Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares rose 8.5% during trading on Friday . The stock traded as high as $1.43 and last traded at $1.41. Approximately 2,127,498 shares traded hands during mid-day trading, an increase of 219% from the average daily volume of 666,314 shares. The stock had previously closed at $1.30.
TTPH has been the topic of several analyst reports. Robert W. Baird reaffirmed a “buy” rating and issued a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, January 7th. B. Riley initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 target price on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Piper Jaffray Companies decreased their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Gabelli downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and an average target price of $4.54.
The company has a market capitalization of $75.61 million, a P/E ratio of -0.54 and a beta of 2.99.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.40). The business had revenue of $4.28 million for the quarter, compared to the consensus estimate of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 432.40% and a negative return on equity of 65.89%. As a group, equities research analysts expect that Tetraphase Pharmaceuticals Inc will post -1.39 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Paloma Partners Management Co purchased a new position in Tetraphase Pharmaceuticals during the 4th quarter valued at $33,000. Gamco Investors INC. ET AL increased its position in Tetraphase Pharmaceuticals by 42.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares during the period. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the 4th quarter valued at $69,000. Rhumbline Advisers increased its position in Tetraphase Pharmaceuticals by 40.6% during the 4th quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares during the period. Finally, Alambic Investment Management L.P. increased its position in Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 69,900 shares during the period. 44.12% of the stock is currently owned by institutional investors and hedge funds.
About Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Read More: What is Compound Interest?
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.